Spectrum Pharmaceuticals Inc.

08/12/2021 | Press release | Distributed by Public on 08/12/2021 14:04

The company is requesting a meeting with the FDA to clarify the remediation timelines regarding the Complete Response Letter (CRL) for ROLONTIS® (eflapegrastim) (Form 8-K)

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.